Figure 5. Regulation of IKAROS-repressed genes in mouse and human B-ALL. (A–C) RNA-seq expression (RPKM) of (A) Emp1/EMP1, (B) Ifitm3/IFITM3, and (C) Ctnnd1/CTNND1 in control and Ikaros-kd murine B-ALL with Dox treatments indicated (left), and the in US B-ALL cohort stratified by IKZF1 mutation status (right). P-values from moderated Student’s t test. (D) Western blots of Ctnnd1 and Ikaros protein expression in multiple independent primary control and Ikaros-kd leukemias. Ikaros-kd samples B038, B027, and B031, and control samples B002 and B005 are transgenic leukemias (Fig. 1 and 2 and S1), whereas RV#1044 and #1040 were generated using the retroviral approach (Fig. S2). Actin is a loading control.
Figure 5.

Regulation of IKAROS-repressed genes in mouse and human B-ALL. (A–C) RNA-seq expression (RPKM) of (A) Emp1/EMP1, (B) Ifitm3/IFITM3, and (C) Ctnnd1/CTNND1 in control and Ikaros-kd murine B-ALL with Dox treatments indicated (left), and the in US B-ALL cohort stratified by IKZF1 mutation status (right). P-values from moderated Student’s t test. (D) Western blots of Ctnnd1 and Ikaros protein expression in multiple independent primary control and Ikaros-kd leukemias. Ikaros-kd samples B038, B027, and B031, and control samples B002 and B005 are transgenic leukemias (Fig. 1 and 2 and S1), whereas RV#1044 and #1040 were generated using the retroviral approach (Fig. S2). Actin is a loading control.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal